Johnson & Johnson Halts Proposed 340B Rebate Model
What’s happening: Johnson & Johnson will stop its plan that would have required hospitals participating in the 340B drug discount program to purchase Stelara and Xarelto at full price and apply for a rebate instead of receiving full discounts upfront.
What else to know: The Health Resources and Services Administration (HRSA) notified J&J it would be kicked out of the 340B Drug Pricing Program if it did not halt implementation.
Ask Reps. to Sign Letter Opposing 340B Program Changes
What’s happening: A bipartisan group of U.S. representatives is leading a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra about efforts by Johnson & Johnson (J&J) to undermine the 340B Drug Discount Program.
What else to know: Hospital leaders should call or email their U.S. representative and urge them to sign on to the letter by Sept. 27.
Hospitals Should Encourage Reps. to Sign Letter Opposing 340B Program Changes
What’s happening: A bipartisan group of U.S. representatives is leading a letter to U.S. Health and Human Services (HHS) Secretary Xavier Becerra about efforts by Johnson & Johnson (J&J) to undermine the 340B Drug Discount Program.
What else to know: The deadline for signatures is expected to be extended but since the House could go out of session at any time, it’s urgent to ask your representative to sign now.
CHA Urges Hospitals to Invite Members of Congress to Visit
What’s happening: CHA issued an alert encouraging members to meet with their representatives to discuss key issues like the 340B Drug Pricing Program, financial instability, prior authorization, rural health care, disproportionate share hospital payment cuts, and site-neutral payment policies.
What else to know: Members of Congress will be back in their districts for the entire month of October. These visits will not only strengthen relationships, but also help educate and inform your representative ahead of critical health care policy votes in December.
Annual 340B Recertification Period for Hospitals Approaching
What’s happening: The Health Resources and Services Administration’s (HRSA) annual 340B Drug Pricing Program recertification window for hospitals will be open from Aug. 12 to Sept. 9.
What else to know: Recertification is required for all hospitals currently participating in the 340B program. Hospitals that do not complete the recertification process will be removed from the 340B program.
CHA Summarizes Finalized Changes to 340B ADR Process
What’s happening: CHA has issued a detailed summary of the final rule updating the 340B administrative dispute resolution (ADR) process.
What else to know: The final rule became effective June 18.
340B and Multiple Federal Issues Simmering
As financial challenges continue to plague California’s hospitals, conversation at the federal level is heating up over 340B, the national discount drug program that serves the most vulnerable patients at nearly 200 hospitals in our state.
Hospital Leaders Discuss Financial Challenges with Legislators on Capitol Hill
What’s happening: Last week, California hospital and health system leaders convened in Washington, D.C. for the American Hospital Association (AHA) Annual Membership Meeting.
What else to know: Hospital and health system leaders participated in meetings on Capitol Hill with the California congressional delegation to advance CHA’s position on key advocacy priorities.
HRSA Implements Long-Awaited Dispute Resolution Process
What’s happening: The Health Resources and Services Administration (HRSA) finalized requirements and procedures for the 340B Drug Discount Program’s administrative dispute resolution (ADR) process.
What else to know: The regulation is effective June 18.
CHA Comments on Draft 340B Legislation
What’s happening: CHA submitted feedback on draft legislation related to the 340B Drug Pricing Program, which allows rural and safety-net hospitals to buy outpatient drugs at discounted prices.
What else to know: The bipartisan SUSTAIN 340B Act considers significant changes to the 340B program.